Acadian Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Acadian Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.66M	Buy	22,252 +1,484	+7%	+$104K	﹤0.01%	1125
2026 Q1	$1.54M	Buy	20,768 +2,044	+11%	+$148K	﹤0.01%	1031
2025 Q4	$1.43M	Buy	+18,724	New	+$1.23M	﹤0.01%	1013
2024 Q4	–	Sell	-6,034	Closed	-$153K	–	1656
2024 Q3	$153K	Buy	+6,034	New	+$158K	﹤0.01%	1458
2023 Q1	–	Sell	-8,843	Closed	-$66K	–	1747
2022 Q4	$66K	Sell	8,843 -37,732	-81%	-$361K	﹤0.01%	1519
2022 Q3	$465K	Buy	46,575 +23,130	+99%	+$240K	﹤0.01%	1009
2022 Q2	$212K	Buy	+23,445	New	+$196K	﹤0.01%	1182

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Acadian Asset Management's BBIO Position: Q2 2026 in Review

Acadian Asset Management increased its BridgeBio Pharma (BBIO) stake by 7.1% in Q2 2026, buying an estimated $104K and bringing the position to 22,252 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Acadian Asset Management first reported a position in BBIO in Q2 2022 and has held it in 7 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Acadian Asset Management held 22,252 shares of BridgeBio Pharma worth $1.66M as of Q2 2026.
Acadian Asset Management bought 1,484 BridgeBio Pharma shares in Q2 2026, an estimated $104K.
BridgeBio Pharma made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1125 holding.
Acadian Asset Management first reported a position in BridgeBio Pharma in Q2 2022 and has held it in 7 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.